ANABV — AnaptysBio Income Statement
0.000.00%
Last trade - 00:00- $1.94bn
- $1.91bn
- $234.60m
Annual income statement for AnaptysBio, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 6 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-KT |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10.3 | 17.2 | 91.3 | 235 | 53 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 125 | 182 | 206 | 187 | 20.7 |
| Operating Profit | -115 | -164 | -115 | 47.9 | 32.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -129 | -164 | -145 | -13.1 | -5.09 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -129 | -164 | -145 | -13.2 | 176 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -129 | -164 | -145 | -13.2 | 131 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -129 | -164 | -145 | -13.2 | 131 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.57 | -5.8 | -5.12 | -0.46 | 4.85 |
| Dividends per Share |